Researchers at Northwell Health in New York are testing the effects on Famotidine (used in high intravenous doses) on Covid-19 patients as a potential treatment. After the hospital announced its clinical trials, it led to a drug shortage in the US. Back home, however, there has not been any surge in the demand for Famotidine yet.
Despite unprecedented levels of uncertainty in Samvat 2077, investors have little to complain about on the returns front. The BSE Sensex delivered returns of 38 per cent in this period, while the Nifty registered a return of over 40 per cent. As is the case in bull markets, companies in the small- and mid-capitalisation basket outperformed the benchmarks, with returns almost twice those of frontliners.
'WHO issued an emergency use listing for Covovax, expanding the basket of WHO-validated vaccines against COVID-19. The vaccine is produced by the Serum Institute of India under licence from Novavax,' the world health body said in a tweet on Friday.
Under terms of the agreed deal, Ranbaxy shareholders will get 0.8 of a Sun Pharmaceutical share for each Ranbaxy share they own.
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
The weakness in the stock was because of inspections by the American drug regulator at its Halol plant in Gujarat which resulted in eight observations, as well as a downward revision of speciality drug payoffs.
'Supplies should start moving to the Serum Institute without any impediments.'
The FDA had imposed a ban on the company's Waluj plant in May.
US District Judge Beryl Howell in Minneapolis denied Ranbaxy's request, the court filing showed.
Calling COVID-19 pandemic and vaccines as one of the most important aspects of his discussions with top officials of the Biden administration, External Affairs Minister S Jaishankar has said the endeavour is to expand production of vaccines in India with assistance from the US.
While the US health regulator did not specify details for issuing the alert, it said 'detention without physical examination may be appropriate when an FDA inspection has revealed that a firm is not operating in conformity with current good manufacturing practices'.
All of Ranbaxy's India-based factories are currently banned by the FDA from exporting medicines to the United States, the company's largest market, after the regulator's inspection found violation of its so-called good manufacturing practices.
Sun Pharma stated the company wanted shareholders' approval to "issue, offer and allot equity shares or non-convertible securities, other than warrants, up to an amount of Rs 12,000 crore ($2 billion), to qualified institutional buyers pursuant to a QIP."
The Oxford/AstraZeneca vaccine is also being produced as part of a tie-up by the Serum Institute of India.
"Due to scheduling reasons, it is inconvenient for China to attend the meeting," Chinese Foreign Ministry spokesman Wang Wenbin told mediapersons.
The introduction of e-pharmacy, to protect the interest of a handful of players, would hamper the interest of 800,000 chemists and 80 lakh workers and their families
Rosier year-end seen for Indian pharma thanks to faster US approvals.
FDA inspectors visited the Mohali plant in the process of giving approval to Ranbaxy's application for Valsartan.
The recalled drugs were manufactured and distributed in the US by Ohm Laboratories.
Inspections only in domestic authorities' presence, visiting US drug regulator told
It had posted net profit of Rs 125.75 crore (Rs 1.25 billion) during the January-March quarter of the previous fiscal, 2012-13.
An end to Sun Pharma founder Dilip Shanghvi's woes are not in sight.
In the next two weeks, the United States will detail plans to equitably distribute about 80 million (8 crore) COVID-19 vaccine doses globally without 'political requirements' of those receiving them, Secretary of State Antony Blinken has said.
The Indian Army on Wednesday issued an advisory asking its personnel not to consume Maggi noodles.
Sayre Therapeutics aims for a spot among top 5 players in oncology.
Low growth visibility and trouble with regulators have resulted in lack of interest from investors
A key lesson for the pharmaceutical sector in this case is to not downplay the significant impact that regulatory non-compliance can have on operations.
GE Healthcare has already filed five global patents for its design.
If a retail investor wants exposure to a healthcare ETF, it should be a part of his satellite portfolio, suggests Sanjay Kumar Singh.
The ICMR is working on a war footing to develop the testing ecosystem -- especially for the screening blood tests. NIV, Pune, is in the process of validating antibody-based screening kits.
This is not just a Ranbaxy or Wockhardt problem, says K Satish Reddy
An International Policy Network report in 2010 found that seven per cent of drugs bought from wholesale traders were substandard, and 3.6 per cent of the drugs from traders contained no active ingredient whatsoever.
In Uttar Pradesh, standards for 'Macaroni products' are being applied for 'Instant Noodles with seasoning' which is erroneous and misleading, alleges Nestle.
This is because while the emergency authorisation for treating Covid was a recent move, the drug has been used since years for rheumatoid arthritis and autoimmune lupus.
Sun Pharma open to large acquisitions post Ranbaxy.
After Maggi, the sample of macroni pasta was taken from Mau and sent to National Food Analysis Laboratory.
Nestle was perceived as being feeble in its defence.
Sensex, Nifty put up a good show in closing trade.
The Supreme Court on Monday posed some tough questions to a lawyer, asking him to substantiate his "unfounded allegations" in a PIL that Indian pharma major Ranbaxy Laboratories Ltd was allegedly manufacturing and selling adulterated medicines.
SII would be scaling up its AstraZeneca-Oxford vaccine manufacturing capacity to 200 million doses a month from 100 million a month now, reports Sohini Das.
